396 related articles for article (PubMed ID: 32862183)
1. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
[TBL] [Abstract][Full Text] [Related]
2. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
[TBL] [Abstract][Full Text] [Related]
3. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab.
Kawashima A; Yamamoto Y; Sato M; Nakata W; Kakuta Y; Ishizuya Y; Yamaguchi Y; Yamamoto A; Yoshida T; Takayama H; Takada T; Inoue H; Okuda Y; Kato T; Hatano K; Uemura M; Nonomura N; Imamura R
Sci Rep; 2021 Oct; 11(1):21199. PubMed ID: 34707147
[TBL] [Abstract][Full Text] [Related]
4. First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T; Nagai T; Sugiyama Y; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Isobe T; Matsumoto D; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2021; 99(10):622-631. PubMed ID: 34284409
[TBL] [Abstract][Full Text] [Related]
5. GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
Sugiyama Y; Naiki T; Tasaki Y; Mimura Y; Etani T; Noda Y; Nozaki S; Shimizu N; Banno R; Nagai T; Isobe T; Ando R; Moritoki Y; Kataoka T; Odagiri K; Aoki M; Gonda M; Yasui T; Hibi Y
Oncology; 2023; 101(4):224-233. PubMed ID: 36689919
[TBL] [Abstract][Full Text] [Related]
6. Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
Karayama M; Inoue Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suda T
BMC Pulm Med; 2021 Dec; 21(1):409. PubMed ID: 34895201
[TBL] [Abstract][Full Text] [Related]
7. The impact of geriatric nutritional risk index on surgical outcomes after esophagectomy in patients with esophageal cancer.
Kubo N; Sakurai K; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Yashiro M; Ohira M
Esophagus; 2019 Apr; 16(2):147-154. PubMed ID: 30311102
[TBL] [Abstract][Full Text] [Related]
8. Geriatric nutritional risk index, muscle function, quality of life and clinical outcome in hemodialysis patients.
Beberashvili I; Azar A; Sinuani I; Shapiro G; Feldman L; Sandbank J; Stav K; Efrati S
Clin Nutr; 2016 Dec; 35(6):1522-1529. PubMed ID: 27117682
[TBL] [Abstract][Full Text] [Related]
9. Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy.
Chang LW; Hung SC; Chen CS; Li JR; Chiu KY; Wang SS; Yang CK; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Yang SF
Sci Rep; 2023 Mar; 13(1):4554. PubMed ID: 36941480
[TBL] [Abstract][Full Text] [Related]
10. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
[TBL] [Abstract][Full Text] [Related]
11. Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial.
Lee GW; Go SI; Kim DW; Kim HG; Kim JH; An HJ; Jang JS; Kim BS; Hahn S; Heo DS
Thorac Cancer; 2020 Jan; 11(1):62-71. PubMed ID: 31707767
[TBL] [Abstract][Full Text] [Related]
12. [A Prognostic Model of Elderly Patients with Non-small Cell Lung Cancer
Based on Geriatric Nutritional Risk Index].
Zhang X; Xiong Y; Xu A
Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):497-506. PubMed ID: 37653013
[TBL] [Abstract][Full Text] [Related]
13. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
[TBL] [Abstract][Full Text] [Related]
14. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
[TBL] [Abstract][Full Text] [Related]
15. Geriatric Nutritional Risk Index as a prognostic factor in patients with esophageal squamous cell carcinoma -retrospective cohort study.
Yamana I; Takeno S; Shimaoka H; Yamashita K; Yamada T; Shiwaku H; Hashimoto T; Yamashita Y; Hasegawa S
Int J Surg; 2018 Aug; 56():44-48. PubMed ID: 29602015
[TBL] [Abstract][Full Text] [Related]
16. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Galsky MD; Mortazavi A; Milowsky MI; George S; Gupta S; Fleming MT; Dang LH; Geynisman DM; Walling R; Alter RS; Kassar M; Wang J; Gupta S; Davis N; Picus J; Philips G; Quinn DI; Haines GK; Hahn NM; Zhao Q; Yu M; Pal SK
J Clin Oncol; 2020 Jun; 38(16):1797-1806. PubMed ID: 32271672
[TBL] [Abstract][Full Text] [Related]
17. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
[TBL] [Abstract][Full Text] [Related]
18. Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Anticancer Res; 2021 Mar; 41(3):1607-1614. PubMed ID: 33788756
[TBL] [Abstract][Full Text] [Related]
19. The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin.
Fujiwara Y; Sato Y; Hayashi N; Fukuda N; Wang X; Nakano K; Ohmoto A; Urasaki T; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takahashi S
J Geriatr Oncol; 2023 Jun; 14(5):101523. PubMed ID: 37229881
[TBL] [Abstract][Full Text] [Related]
20. Geriatric nutritional risk index as a nutritional and survival risk assessment tool in stable outpatients with systolic heart failure.
Sargento L; Vicente Simões A; Rodrigues J; Longo S; Lousada N; Palma Dos Reis R
Nutr Metab Cardiovasc Dis; 2017 May; 27(5):430-437. PubMed ID: 28438373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
